Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion

Table 2 Tyrosine kinase inhibitor approved as an adjuvant therapy for hepatocellular carcinoma patients with microvascular invasion

NCT number	Title	Interventions	Characteristics	n	Date	Current status
NCT02678806	Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (< 1 cm) and/or Microvascular Invasion (RHCC:BCLC-A)	Radiation: Postoperative radiotherapy. Drug: Postoperative TACE	Phase: Not applicable. Allocation: Randomized. Intervention model: Parallel. Outcome measures: Overall survival	620	November 1, 2017 to November 1, 2022	Recruiting
NCT04053972	The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy: A Random, Controlled, Stage III Clinical Trial	Drug: Lenvatinib	Phase: 3. Allocation: Randomized. Intervention model: Parallel. Outcome measures: RFS and OS recurrence rate	377	January 31, 2018 to December 31, 2022	Recruiting
NCT02867280	Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection	Drug: Sorafenib	Phase: 3. Allocation: Non_x005f randomized. Outcome measures: Recurrence free survival; time to recurrence; recurrence rate; overall survival; incidence of treatment related; adverse events; incidence of dose modification of sorafenib due to adverse events	154	June 1, 2016 to January 31, 2020	Terminated
NCT03192618	The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy: A Random, Controlled, Stage III Clinical Trial	Procedure: Adjuvant transarterial chemoinfusion. Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-fluorouracil)	Phase: 3. Allocation: Randomized. Outcome measures: DFS; recurrence rate; OS	290	July 1, 2017 to December 31, 2024	Recruiting
NCT02436902	Adjuvant Therapies for Patients With HCC and MVI	Procedure: TACE. Drug: Sorafenib, TACE plus sorafenib and empty control	Phase: 3. Allocation: Non_x005f randomized. Outcome measures: Overall survivals; hospital mortality; recurrence rates	240	February 1, 2019 to August 30, 2022	Recruiting
NCT03732105	Radiotherapy/Apatinib for Adjuvant Treatment of HCC Patients receIved Curative resection With Microvascular Invasion	Radiotherapy. Drug: Apatinib and radiotherapy + apatinib	Phase: 2. Allocation: Randomized. Outcome measures: RFS; time to recurrence; overall survival; safety events; health related quality of life	160	November 1, 2018 to December 31, 2023	Not yet recruiting
NCT03575806	Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection	Combination product: TACE plus autologous Tcm immunotherapy. Procedure: TACE	Phase: 2. Allocation: Non_x005f randomized. Outcome measures: RFS time; OS rate at 24 mo	52	January 9, 2017 to October 31, 2019	Completed
	Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?	Drug: Sorafenib	Phase: Not applicable. Allocation: Retrospective study. Outcome measures: DFS; recurrence rate; OS	49	January, 2009 to December, 2016	Completed
	Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma	Procedure: TACE. Drug: Sorafenib, TACE plus sorafenib, and TACE	Phase: Not applicable. Allocation: Retrospective study. Outcome measures: DFS; recurrence rate; OS	127	January, 2010 to December, 2016	Completed
	Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis	Drug: Sorafenib	Phase: Not applicable. Allocation: Retrospective study. Outcome measures: DFS; recurrence rate; OS	728	January, 2009 to December, 2016	Completed
NCT00692770	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial	Drug: Sorafenib	Phase: 3. Allocation: Randomized. Outcome measures: DFS; recurrence rate; OS	1114	August 15, 2008 to November 17, 2010	Completed

TACE: Transcatheter arterial chemoembolization; DFS: Disease-free survival; OS: Overall survival; RFS: Recurrence-free survival; HCC: Hepatocellular carcinoma; MVI: Microvascular invasion.